drugset / Trial / NCT04391985
Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
enrolled participants were treated orally with SOF plus a fixed dose combination of OBV/PTV/r plus RBV.
Timeline
- Start
- 2017-03-01
- Primary completion
- 2017-10-31
- Completion
- 2017-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ribavirin | Small molecule | 600 mg | Oral |
| Comparator | Ribavirin | Small molecule | 1200 mg | Oral |
| Comparator | Ritonavir | Other / unclassified | 100 mg | Oral |
| Comparator | Sofosbuvir | Small molecule | 400 mg | Oral |
| Comparator | ombitasvir | Small molecule | 25 mg | Oral |
| Comparator | paritaprevir | Small molecule | 150 mg | Oral |